Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluticasone Propionate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 11/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.61 |
| ▸ | PGR | P06401 | 4/20 | 0.61 |
| ▸ | AR | P10275 | 4/20 | 0.61 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.61 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.61 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | IL5 | P05113 | 1/20 | 0.61 |
| ▸ | MMP9 | P14780 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | THPO | P40225 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluticasone Propionate SCHEMBL5566344 | 0.87 | NR3C1 (0.66) | NR3C1CYP3A4PGRARNR3C2 | |
| Ciclesonide SCHEMBL17435231 | 0.85 | NR3C1 (0.63) | NR3C1CYP3A4PGRARNR3C2 | |
| Fluticasone Propionate SCHEMBL1692016 | 0.84 | NR3C1 (0.67) | NR3C1CYP3A4PGRARNR3C2 | |
| Fluticasone Propionate SCHEMBL4281973 | 0.82 | NR3C1 (0.70) | NR3C1CYP3A4PGRARNR3C2 | |
| Beclomethasone Dipropionate SCHEMBL266055 | 0.81 | NR3C1 (0.65) | NR3C1CYP3A4PGRARNR3C2 | |
| Betamethasone Valerate SCHEMBL8449742 | 0.80 | NR3C1 (0.64) | NR3C1CYP3A4PGRARNR1I2 | |
| Dexbudesonide SCHEMBL18695366 | 0.80 | CYP3A4 (0.73) | NR3C1CYP3A4PGRARNR3C2 | |
| Dexbudesonide SCHEMBL4260550 | 0.80 | CYP3A4 (0.73) | NR3C1CYP3A4PGRARNR3C2 | |
| Rofleponide SCHEMBL4098718 | 0.79 | NR3C1 (0.64) | NR3C1CYP3A4PGRARNR3C2 | |
| Fluticasone Propionate SCHEMBL28834034 | 0.79 | NR3C1 (0.70) | NR3C1CYP3A4PGRARNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385494-A2 | AEROSOL COMPOSITIONS CONTAINING FORMOTEROL AND A STEROID SUCH AS E.G. BUDESONIDE OR FLUTICASONE FOR DELIVERY INTO THE LUNGS | Dey L.P. (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030055026-A1 | Intended for administration as a nebulized aerosol; for therapy and prophylaxis symptoms of bronchocon-strictive disorders | DEY L.P. | 2003-03-20 | — | — | US | disclosed |
| WO-2002083113-A2 | AEROSOL COMPOSITIONS CONTAINING FORMOTEROL AND A STEROID SUCH AS E.G. BUDESONIDE OR FLUTICASONE FOR DELIVERY INTO THE LUNGS VIA NEBULIZATION | DEY, L.P. (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055026-A1 | Intended for administration as a nebulized aerosol; for therapy and prophylaxis symptoms of bronchocon-strictive disorders | SERPINA6, CALU, TSLP | NR3C1 15/4885CYP3A4 3255/4885PGR 4203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.